Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ana Cláudia Lima, Helena Ferreira, Rui L. Reis & Nuno M. Neves. (2019) Biodegradable polymers: an update on drug delivery in bone and cartilage diseases. Expert Opinion on Drug Delivery 16:8, pages 795-813.
Read now
Read now
Priyanka Vashisht & James O’dell. (2017) Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert Opinion on Biological Therapy 17:8, pages 989-999.
Read now
Read now
Maricel G Miguelino & Jerry S Powell. (2014) Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B. Patient Preference and Adherence 8, pages 1073-1083.
Read now
Read now
Jonathan M Ducore, Maricel G Miguelino & Jerry S Powell. (2014) Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B. Expert Review of Hematology 7:5, pages 559-571.
Read now
Read now
Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Nobuyuki Miyasaka & Takao Koike. (2014) Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Modern Rheumatology 24:5, pages 734-743.
Read now
Read now
Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Toshiharu Shoji, Nobuyuki Miyasaka & Takao Koike. (2014) Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Modern Rheumatology 24:5, pages 725-733.
Read now
Read now
Homa Timlin & Clifton O Bingham$suffix/text()$suffix/text(). (2014) Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert Opinion on Biological Therapy 14:7, pages 893-904.
Read now
Read now
Marie Fechtenbaum, Md Yuzaiful Md Yusof & Paul Emery. (2014)
Certolizumab pegol in rheumatoid arthritis: current update. Expert Opinion on Biological Therapy 14:6, pages 841-850.
Read now
Read now
Hubert Marotte & Rolando Cimaz. (2014) Etanercept – TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers?. Expert Opinion on Biological Therapy 14:5, pages 569-572.
Read now
Read now
Articles from other publishers (28)
Yogesh Dutt, Ramendra Pati Pandey, Mamta Dutt, Archana Gupta, Arpana Vibhuti, Jasmina Vidic, V. Samuel Raj, Chung-Ming Chang & Anjali Priyadarshini. (2023) Therapeutic applications of nanobiotechnology. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Chenyu ZhangPeixiang MaAn QinLiao WangKerong DaiYuanyuan LiuJie ZhaoZuyan Lu. (2023) Current Immunotherapy Strategies for Rheumatoid Arthritis: The Immunoengineering and Delivery Systems. Research 6.
Crossref
Crossref
Clóvis Dervil Appratto Cardoso Júnior, Bruna Xavier, Rafaela Ferreira Perobelli Dumoncel, Francielle Santos da Silva & Sérgio Luiz Dalmora. (2023) Quantitation of certolizumab pegol by validated liquid chromatography methods. Brazilian Journal of Pharmaceutical Sciences 59.
Crossref
Crossref
Dipayan Roy, Anupama Modi, Ritwik Ghosh & Julián Benito-León. 2023. Antiviral and Antimicrobial Coatings Based on Functionalized Nanomaterials. Antiviral and Antimicrobial Coatings Based on Functionalized Nanomaterials
447
484
.
Joana M. O. Santos, Alexandra C. Costa, Tânia R. Dias, Setareh Satari, Maria Paula Costa e Silva, Rui M. Gil da Costa & Rui Medeiros. (2021) Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates. Pharmaceuticals 14:11, pages 1084.
Crossref
Crossref
Abuzer Alp Yetisgin, Sibel Cetinel, Merve Zuvin, Ali Kosar & Ozlem Kutlu. (2020) Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules 25:9, pages 2193.
Crossref
Crossref
Peter L. Turecek & Jürgen Siekmann. 2020. Polymer-Protein Conjugates. Polymer-Protein Conjugates
61
101
.
Andreas Baumann, Isabel Piel, Frank Hucke, Steffen Sandmann, Terence Hetzel & Thomas Schwarz. (2019) Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction. European Journal of Pharmaceutical Sciences 130, pages 11-20.
Crossref
Crossref
Andrea Rubbert-Roth, Fabiola Atzeni, Ignazio Francesco Masala, Roberto Caporali, Carlomaurizio Montecucco & Piercarlo Sarzi-Puttini. (2018) TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. Autoimmunity Reviews 17:1, pages 24-28.
Crossref
Crossref
Sahar Awwad, Claire Ginn & Steve Brocchini. 2018. Engineering of Biomaterials for Drug Delivery Systems. Engineering of Biomaterials for Drug Delivery Systems
27
49
.
Peter L. Turecek, Mary J. Bossard, Freddy Schoetens & Inge A. Ivens. (2016) PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs. Journal of Pharmaceutical Sciences 105:2, pages 460-475.
Crossref
Crossref
Thomas McDonnell, Charis Pericleous, Emmanuelle Laurine, Rita Tommasi, Acely Garza-Garcia, Ian Giles, Yiannis Ioannou & Anisur Rahman. (2015) Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. BMC Biotechnology 15:1.
Crossref
Crossref
J.S. Powell. (2015) Longer‐acting clotting factor concentrates for hemophilia. Journal of Thrombosis and Haemostasis 13, pages S167-S175.
Crossref
Crossref
Mehdi Boroujerdi. 2015. Pharmacokinetics and Toxicokinetics. Pharmacokinetics and Toxicokinetics
447
460
.
Jerry S. Powell. (2014) Lasting power of new clotting proteins. Hematology 2014:1, pages 355-363.
Crossref
Crossref
Leonardo Punzi, Giovanni Lapadula & Alessandro Mathieu. (2014) Efficacy and Safety of Certolizumab Pegol in Rheumatoid Arthritis: Meeting Rheumatologists? Requirements in Routine Clinical Practice. BioDrugs 28:S1, pages 25-37.
Crossref
Crossref
Pamela J. Hornby, Philip R. Cooper, Connie Kliwinski, Edwin Ragwan, John R. Mabus, Benjamin Harman, Suzanne Thompson, Amanda L. Kauffman, Zhengyin Yan, Susan H. Tam, Haimanti Dorai, Gordon D. Powers & Jill Giles-Komar. (2013) Human and Non-Human Primate Intestinal FcRn Expression and Immunoglobulin G Transcytosis. Pharmaceutical Research 31:4, pages 908-922.
Crossref
Crossref
T. McDonnell, Y. Ioannou & A. Rahman. (2013) PEGylated drugs in rheumatology--why develop them and do they work?. Rheumatology 53:3, pages 391-396.
Crossref
Crossref
Rajesh A. Shenoi, Fang Gao, Muhammad Imran Ul-Haq & Jayachandran N. Kizhakkedathu. 2014. Chemistry of Bioconjugates. Chemistry of Bioconjugates
77
103
.
Bernard Ng & Adeline Chu. (2013) Factors associated with methotrexate dosing and therapeutic decisions in veterans with rheumatoid arthritis. Clinical Rheumatology 33:1, pages 21-30.
Crossref
Crossref
Randal J. Kaufman & Jerry S. Powell. (2013) Molecular approaches for improved clotting factors for hemophilia. Hematology 2013:1, pages 30-36.
Crossref
Crossref
Randal J. Kaufman & Jerry S. Powell. (2013) Molecular approaches for improved clotting factors for hemophilia. Blood 122:22, pages 3568-3574.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Rheumatology 25:3, pages 398-409.
Crossref
Crossref
Fabiola Atzeni, Maurizio Benucci, Salvatore Sallì, Sara Bongiovanni, Laura Boccassini & Piercarlo Sarzi-Puttini. (2013) Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews 12:5, pages 575-579.
Crossref
Crossref
I. A. Ivens, A. Baumann, T. A. McDonald, T. J. Humphries, L. A. Michaels & P. Mathew. (2013) PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 19:1, pages 11-20.
Crossref
Crossref
Xin Xu & Yulia Vugmeyster. (2012) Challenges and Opportunities in Absorption, Distribution, Metabolism, and Excretion Studies of Therapeutic Biologics. The AAPS Journal 14:4, pages 781-791.
Crossref
Crossref
Alfreda D. Nelson, Michele M. Hoffmann, Christopher A. Parks, Surendra Dasari, Adam G. Schrum & Diana Gil. (2012) IgG Fab Fragments Forming Bivalent Complexes by a Conformational Mechanism That Is Reversible by Osmolytes. Journal of Biological Chemistry 287:51, pages 42936-42950.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Rheumatology 24:3, pages 342-349.
Crossref
Crossref